SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending following its preliminary Q3 revenue exceeding expectations, sparking a surge of investor enthusiasm. The community is actively discussing the company's substantial year-over-year growth and its reinforced position as a crucial 'picks and shovels' provider for the expanding AI data center infrastructure.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl (KD) is experiencing an intense sell-off and community debate following the abrupt departures of its CFO and general counsel amid an ongoing accounting review, delayed regulatory filings, and reduced financial guidance. While many see the over 50% plunge as an extreme overreaction and a potential buying opportunity, others express deep concern over financial irregularities, referencing a past short report, and caution against further downside.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is generating strong community buzz as its AI-powered ecosystem expands with new exchange listings and cross-chain integrations, leading many to anticipate significant price milestones and further utility growth.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is trending following its recent NASDAQ listing and a significant $50 million financing, sparking intense debate around its novel Duchenne Muscular Dystrophy drug, SAT-3247. The community is split between those hailing its "revolutionary" muscle regeneration potential and acquisition prospects, and skeptics citing its early-stage data and concerns over dilution.

NexGen Energy Ltd. engages in the acquisition, exploration and development of uranium properties. Its uranium project portfolio includes Arrow, South Arrow, Harpoon, Bow, IsoEnergy, SW1, SW2, SW3, and IsoEnergy properties. The company was founded by Leigh B. Curyer on March 8, 2011 and is headquartered in Vancouver, Canada.

NexGen Energy Ltd

NexGen Energy (NXE) is trending following a critical short report from Culper Research that challenged its valuation and production capabilities, sparking a strong defense from the community. Investors are refuting the report's claims, underscoring the company's world-class uranium deposit and its strategic role in meeting rising global nuclear and AI-driven energy demand as it approaches key regulatory milestones.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is gaining traction from new ballistic optics orders for U.S. military augmented reality systems and increasing demand for its space and AI data center optics. The community is actively debating its low float and significant growth potential from defense and AI tailwinds against concerns over its current valuation and cash position.

Symbotic, Inc. is an automation technology company, which engages in a robotics and automation-based product movement technology platform. It focuses on developing, commercializing, and deploying innovative, end-to-end technology solutions for supply chain operations. It operates through the United States and Canada geographical segments. The company was founded by Richard B. Cohen on December 11, 2020 and is headquartered in Wilmington, MA.

Symbotic Inc - Ordinary Shares - Class A

Symbotic Inc 

Symbotic is trending after reporting strong earnings that exceeded profit expectations and showed significant revenue growth, alongside a new healthcare customer deal. The community is actively discussing its sharp recovery after a volatile period marked by a secondary offering and a major analyst downgrade, emphasizing its long-term potential in AI robotics and warehouse automation despite ongoing valuation concerns.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Energy and Transportation, Financial Products, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Energy and Transportation segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The Financial Products segment provides financing alternatives to customers and dealers for Caterpillar products and services, as well as financing for power generation facilities. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925 and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending sharply higher after reporting strong results, with its energy and transportation segments seeing significant growth attributed to booming AI-driven data center demand. While bullish investors celebrate record backlogs and a market rotation into industrials, a vocal segment expresses skepticism about the valuation and potential for a significant pullback.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors react to the inauguration of its Eagle Line pilot production facility, signaling a crucial step towards scalable solid-state battery manufacturing. The community is actively debating whether this progress, including observed OEM presence, translates to imminent commercialization and new partnerships, or if skepticism over revenue and formal customer announcements will persist ahead of upcoming earnings.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Federal National Mortgage Association (FNMA) is trending amidst renewed speculation of an imminent uplisting to the NYSE or an IPO, fueled by recent comments from FHFA Director Pulte indicating readiness for a public offering and a brief appearance of an NYSE listing manual on Fannie Mae's website. The community remains divided between hopeful long-term investors anticipating significant returns and those expressing deep frustration over prolonged delays and political maneuvering surrounding the GSEs' future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sunshine Biopharma (SBFM) rose 11% on Thursday morning after the company announced that its Canadian unit, Nora Pharma, launched a generic version of Bristol-Myers Squibb’s Pravachol.The drug, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/10/20251016_SBFM_Press-Release_Launches-Pravastatin.pdf">called</a> Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.Nora Pharma’s Pravastatin is available in strengths of 10 mg, 20 mg, and 40 mg, and comes in bottles of 100 tablets.Sunshine Biopharma said that the Canadian market of cholesterol-lowering drugs is estimated to reach $582 million by the end of 2025 and $1.07 billion by 2033.Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada, and more than 12 additional drugs are scheduled to be launched in 2026. The company is also seeking to develop drug candidates in the treatment of liver cancer and coronavirus infections.On Stocktwits, retail sentiment around SBFM stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_16_at_10_55_53_AM_png_97567a6c3b.webp" alt="SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>SBFM's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Oct. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user believes the company has a bright future.<stembedurl>https://stocktwits.com/Knowledgeworthmore/message/632572691</stembedurl>Another said that they intend to hold the stock long term.<stembedurl>https://stocktwits.com/BanditKnight47/message/632549060</stembedurl>In July, Sunshine Bioopharma <a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-stock-soars-after-launch-of-first-biosimilar-in-10-b-canadian-market-retail-bulls-charge-in/chFjax5Rchk">introduced</a> its first biosimilar drug, Niopeg, to the Canadian market, to treat the risk of infection in cancer patients undergoing chemotherapy. In June, a generic version of Neurontin, Gabapentin, was launched for treating neuropathic pain and epilepsy.SBFM stock is down by 29% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-draws-investor-interest-as-european-regulator-reportedly-terms-door-safety-a-priority/ch6p3LDR3nA">Tesla Stock Draws Investor Interest As European Regulator Reportedly Terms Door Safety A Priority</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.

Equity

The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.


Retail chatter around Sunshine Biopharma surged late Wednesday after the company introduced Niopeg, its first biosimilar drug, into the Canadian market,&nbsp;sending its stock soaring by nearly 14% — its best session in over seven months.The treatment, developed by its subsidiary Nora Pharma, is a pegfilgrastim biosimilar to Neulasta, which is commonly used to reduce the risk of infection in cancer patients undergoing chemotherapy.Niopeg is supplied in a 6mg/0.6mL prefilled syringe and is designed for patients with non-myeloid cancers.&nbsp;The company noted that global demand for Neulasta and similar drugs was worth approximately $4.5 billion last year, with expectations that it could rise to $9.2 billion by 2033, driven by increasing cancer cases and wider chemotherapy use.Canada, although a smaller part of the global market, still plays a disproportionately large role in biologics spending, according to a statement released by the company.&nbsp;The company said that Canada’s biologic drug sales totaled approximately $10 billion in 2020, accounting for roughly one-third of all pharmaceutical expenditures. Biosimilars, such as Niopeg, have gained more traction there in recent years, helped by provincial policies that encourage switching from branded biologics.The launch follows last month’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sunshine-biopharma-unit-launches-generic-anticonvulsant-in-canada/chlayAARbC6">rollout of a generic version of Gabapentin</a>, a standard treatment for neuropathic pain and epilepsy, now available in 100 mg, 300 mg, and 400 mg doses, packaged in bottles of 500 capsules.Sunshine Biopharma states that it currently has 72 generic drugs on the Canadian market and plans to introduce more before the end of the year. It’s also pursuing drug candidates in areas such as liver cancer and treatments related to the coronavirus.On Stocktwits, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/SBFM">Sunshine Biopharma</a> was ‘extremely bullish’ amid a 6,200% jump in 24-hour message volume.One user noted that for the first time in a long while, Sunshine Biopharma was holding onto its gains following a news release, calling the chart setup strong and suggesting the stock could be gearing up for a multi-day run.<stembedurl>https://stocktwits.com/Tryitin/message/619793472</stembedurl>Another user pointed to the significance of the product launch into a $10 billion market and expressed confidence that the stock could see substantial upside in the coming days, even speculating about a potential move into double digits.<stembedurl>https://stocktwits.com/Tryitin/message/619760589</stembedurl>The stock has declined 42.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In

The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients.

Shares of Sunshine Biopharma Inc. (SBFM) were in the spotlight on Wednesday after the pharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://sunshinebiopharma.com/wp-content/uploads/2025/06/20250611_SBFM_Press-Release_Launches-Gabapentine-1.pdf">announced</a> that its Canadian unit, Nora Pharma, has launched a new generic prescription drug, Gabapentin.Gabapentin is an anticonvulsant medication used to treat neuropathic pain and epilepsy, as well as for the treatment of pain caused by various medical conditions by reducing excess excitation of the neural networks in the brain and spinal cord.Nora Pharma’s Gabapentin is available in strengths of 100 mg, 300 mg, and 400 mg and comes in bottles of 500 capsules.According to Sunshine Pharma, Canada represents approximately 1.2% of the global pharmaceutical market for Gabapentin, which was valued at $1.92 billion in 2024. It is projected to reach $3.07 billion, the company said.CEO Steve Slilaty said that the company is attempting to fortify its presence in Canada’s generic drugs market, valued at $9.4 billion. The market is forecasted to nearly double to $19.2 billion by 2032, he added.Sunshine Biopharma currently has 71 generic prescription drugs on the market in Canada, with over 12 additional drugs planned for launch in the remainder of 2025.On Stocktwits, retail sentiment around SBFM jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_1_14_32_PM_png_31faf5b9e5.webp" alt="SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits" width="631" height="67"><figcaption>SBFM's Sentiment Meter and Message Volume as of 1:14 p.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that short sellers will not risk shorting Sunshine owing to its significant institutional ownership, low float, and ‘HUGE potential.’<stembedurl>https://stocktwits.com/LH1975New/message/617532142</stembedurl><a href="https://stocktwits.com/symbol/SBFM">SBFM stock</a> is down by about 46% this year and has wiped out nearly three-quarters of its valuation over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/intelligent-bio-rises-on-partnership-with-smartox/chlaUpbRbCy">Intelligent Bio Rises On Partnership With Smartox To Expand US Market Presence: Retail Hopes The Stock To Hit $2.6</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’

CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion.

Sunshine Biopharma, Inc.'s stock rose over 3% on Monday, lifting retail investor sentiment, after the company said its Canadian subsidiary had launched a generic version of an oncology drug.Nora Pharma launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market, Sunshine said.&nbsp;The drug is indicated for advanced renal cell carcinoma, breast cancer in certain post-menopausal women, some neuroendocrine tumors and tuberous sclerosis-related brain tumors.&nbsp;Sunshine said Everolimus is available in 2.5 mg, 5 mg and 10 mg strengths in 30-tablet blister packs.The global Everolimus market is valued at $2.5 billion in 2023 and is projected to hit around $4.8 billion by 2032, the company said.&nbsp;The announcement sent message volume on Stocktwits about Sunshine Biopharma soaring over 14,700% in the 24 hours to late Monday, even as the stock slid over 1% in after-hours trading.Sentiment among retail traders flipped to ‘extremely bullish’ from ‘bearish’ a day ago.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SBFM_sentiment_and_message_volume_as_of_April_21_png_ee65768271.webp" alt="SBFM sentiment and message volume as of April 21.png" width="1318" height="316"><figcaption>SBFM sentiment and message volume as of April 21. | source: Stocktwits</figcaption></figure>One watcher took heart from Everolimus' sales projections and said it "is going to blow someday."<stembedurl>https://stocktwits.com/JdNews/message/612158515</stembedurl>Another user speculated that the company was soon going to form strategic partnerships.<stembedurl>https://stocktwits.com/contra7/message/612209836</stembedurl>Earlier this month, Sunshine reported new preclinical data for its K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma (HCC).&nbsp;Sunshine’s stock, which has a short interest of 6.6% according to Koyfin, has lost over half its value this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug

Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market.

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

Sunshine Biopharma Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

SBFM
Sunshine Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SBFM News

SBFMSunshine Biopharma Inc